Compare · MMM vs PLSE
MMM vs PLSE
Side-by-side comparison of 3M Company (MMM) and Pulse Biosciences Inc (PLSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and PLSE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $85.26B, about 26.2x PLSE ($3.25B).
- Over the past year, MMM is up 7.8% and PLSE is up 153.5% - PLSE leads by 145.7 points.
- MMM has been more active in the news (12 items in the past 4 weeks vs 7 for PLSE).
- MMM has more recent analyst coverage (25 ratings vs 8 for PLSE).
- Company
- 3M Company
- Pulse Biosciences Inc
- Price
- $164.68-0.33%
- $44.36-2.82%
- Market cap
- $85.26B
- $3.25B
- 1M return
- -0.03%
- -12.33%
- 1Y return
- +7.81%
- +153.49%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 8
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Latest MMM
- Amendment: SEC Form SCHEDULE 13G/A filed by 3M Company
- 13-Year-old Raji Doshi named America's Top Young Scientist for inventing an algae-aragonite alkalinity system to reduce CO2-driven ocean acidification
- SEC Form 4 filed by 3M Company
- SEC Form 4 filed by 3M Company
- SEC Form 4 filed by 3M Company
- SEC Form 3 filed by 3M Company
- 3M Announces Upcoming Investor Event
- EVP & Chief Financial Officer Maheshwari Anurag exercised 10,944 shares at a strike of $163.02 and covered exercise/tax liability with 4,991 shares, increasing direct ownership by 93% to 12,365 units (SEC Form 4)
- Wells Fargo initiated coverage on 3M with a new price target
- 3M upgraded by Bernstein with a new price target
Latest PLSE
- SEC Form 8-K filed by Pulse Biosciences Inc
- Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
- SEC Form 8-K filed by Pulse Biosciences Inc
- Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
- BTIG Research initiated coverage on Pulse Biosciences with a new price target
- SEC Form 424B5 filed by Pulse Biosciences Inc
- Pulse Biosciences Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits